Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + chloroquine
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Azithromycin + chloroquine is a fixed-dose combination of two small-molecule drugs, azithromycin (a macrolide antibiotic) and chloroquine (an antimalarial agent). This combination has been developed primarily for the treatment and prevention of malaria, including in areas with chloroquine-resistant Plasmodium falciparum. Azithromycin acts by inhibiting bacterial protein synthesis via binding to the 50S ribosomal subunit, while also exhibiting some antimalarial activity through delayed death effects on parasites. Chloroquine interferes with parasite heme detoxification within erythrocytes, leading to toxic buildup and parasite death. The combination may provide additive or synergistic effects against malaria parasites and can also help prevent or treat concurrent bacterial infections. It has been studied as a weekly prophylactic regimen in pregnancy and for uncomplicated malaria treatment[1][2][5][7][8]. Cardiac safety concerns exist due to potential QT prolongation when these agents are combined[3][6].
- Other names
- azithromycin-chloroquine fixed-dose combination
02
Targets
Bacterial 50S ribosomal subunitPfFV heme (Plasmodium falciparum food vacuole heme)PfATP4 (Plasmodium falciparum ATPase 4)β-Hematin
Beyond the preview
Go deeper on azithromycin + chloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + chloroquine.